Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

The HER2 protooncogene encodes a receptor tyrosine kinase, p185HER2. The overexpression of p185HER2 has been associated with a worsened prognosis in certain human cancers. In the present work we have screened a variety of different tumor cell lines for p185HER2 expression using both enzyme-linked immunosorbent and fluorescence-activated cell sorting assays employing murine monoclonal antibodies directed against the extracellular domain of the receptor. Increased levels of p185HER2 were found in breast (5/9), ovarian (1/6), stomach (2/3) and colorectal (5/16) carcinomas, whereas all kidney and submaxillary adenocarcinoma cell lines tested were negative. Some monoclonal antibodies directed against the extracellular domain of p185HER2 inhibited growth in monolayer culture of breast and ovarian tumor cell lines overexpressing p185HER2, but had no effect on the growth of colon or gastric adenocarcinomas expressing increased levels of this receptor. The most potent growth-inhibitory anti-p185HER2 monoclonal antibody in monolayer culture, designated mumAb 4D5 (a murine IgG1κ antibody), was also tested in soft-agar growth assays for activity against p185HER2-overexpressing tumor cell lines of each type, with similar results. In order to increase the spectrum of tumor types potentially susceptible to monoclonal antibody-mediated anti-p185HER2 therapies, to decrease potential immunogenicity issues with the use of murine monoclonal antibodies for human therapy, and to provide the potential for antibody-mediated cytotoxic activity, a mouse/human chimeric 4D5 (chmAb 4D5) and a “humanized” 4D5 (rhu)mAb 4D5 HER2 antibody were constructed. Both engineered antibodies, in combination with human peripheral blood mononuclear cells, elicited antibody-dependent cytotoxic responses in accordance with the level of p185HER2 expression. Since this cytotoxic activity is independent of sensitivity to mumAb 4D5, the engineered monoclonal antibodies expand the potential target population for antibody-mediated therapy of human cancers characterized by the overexpression of p185HER2.

[1]  J. Elam,et al.  Rescue breathing: a modification. , 1959, Lancet.

[2]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[3]  J. Minna,et al.  Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.

[4]  J. Rhim,et al.  Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. , 1989, Cancer research.

[5]  G. Riou,et al.  Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. , 1988, Oncogene research.

[6]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[7]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[8]  T. Shuin,et al.  Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. , 1988, Cancer research.

[9]  M. Shibuya,et al.  Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.

[10]  T. Kameda,et al.  Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. , 1990, Cancer research.

[11]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[12]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[13]  Y. Shiloh,et al.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. , 1988, Cancer research.

[14]  J. Berek,et al.  Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. , 1990, Cancer research.

[15]  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene , 1992, The Journal of experimental medicine.

[16]  M. Yoshida,et al.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line , 1986, Molecular and cellular biology.

[17]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[18]  D. Horsfall,et al.  The significance of oncogene amplification in primary breast cancer , 1989, International journal of cancer.

[19]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[20]  K. Semba.  A v-erbB-related protooncogene, c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma , 1985 .

[21]  M. Schwab,et al.  Cytogenetics and DNA amplification in colorectal cancers , 1990, Genes, chromosomes & cancer.

[22]  R. Weinberg,et al.  p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity , 1986, Molecular and cellular biology.

[23]  W. P. Schneider,et al.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. , 1990, Cancer research.

[24]  I. Verma,et al.  Expression of cellular oncogenes in human malignancies. , 1984, Science.

[25]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[28]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[29]  C. Kotts,et al.  ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. , 1990, Journal of immunological methods.

[30]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[31]  Y H Xu,et al.  Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. , 1984, Science.

[32]  N. Katsuta,et al.  Expression of c-erbB-2 gene product in urinary bladder cancer. , 1991, The Journal of urology.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[34]  K. Hatch,et al.  Oncogene alterations in endometrial carcinoma. , 1990, Gynecologic oncology.

[35]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[37]  Takuma Sasaki,et al.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.

[38]  G. Hortobagyi,et al.  Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. , 1988, Cancer research.

[39]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[40]  D. Weiner,et al.  Expression of c-erbB-2 in human pancreatic adenocarcinomas. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.

[41]  J. A. Fernandez-Pol.  Epidermal growth factor receptor of A431 cells. Characterization of a monoclonal anti-receptor antibody noncompetitive agonist of epidermal growth factor action. , 1985, The Journal of biological chemistry.

[42]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[43]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[44]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[45]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[46]  M. Freeman,et al.  Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. , 1989, Cancer research.

[47]  J. Roth,et al.  Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. , 1989, Cancer research.

[48]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[49]  M. Winget,et al.  p 185 HER 2 Monoclonal Antibody Has An ( iproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor , 2022 .

[50]  M. Greene,et al.  Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. , 1988, Oncogene.

[51]  R. R. Robinson,et al.  Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[53]  D. Clarke-Pearson,et al.  Overexpression of HER‐2/neu in endometrial cancer is associated with advanced stage disease , 1991, American journal of obstetrics and gynecology.

[54]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[55]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[56]  Wen-Hwa Lee,et al.  Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[57]  J. Lillehaug,et al.  Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. , 1988, British Journal of Cancer.

[58]  M. Mathieu,et al.  Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance , 1989, International journal of cancer.

[59]  R. Makuch,et al.  myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. , 1988, Cancer research.

[60]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  W. Benedict,et al.  Erratum: Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[62]  P. Gariglio,et al.  In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. , 1988, Journal of the National Cancer Institute.

[63]  B. Groner,et al.  Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines , 1989, Journal of cellular biochemistry.

[64]  L. M. Smith,et al.  Human immune response to multiple injections of murine monoclonal IgG. , 1985, Journal of immunology.

[65]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[66]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[67]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[68]  R. Weinberg.  ras Oncogenes and the molecular mechanisms of carcinogenesis. , 1984, Blood.

[69]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[70]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[71]  N. Nomura,et al.  High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. , 1986, Cancer research.

[72]  A. Lage,et al.  Epidermal growth factor receptors in human breast cancer , 2005, Breast Cancer Research and Treatment.

[73]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[74]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[75]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.